Overview

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Status:
Active, not recruiting

Trial end date:
2024-02-01

Target enrollment:

Participant gender:

Summary

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment naïve and to compare lorlatinib to crizotinib with respect to overall survival in the same population

Phase:

Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Crizotinib